Nuvelo (Nasdaq: NUVO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Nuvelo (Nasdaq: NUVO)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: SemiBull who wrote (279)	11/13/2003 7:29:52 PM
From: SemiBull	Read Replies (1) of 286

Phase 1 Alfimeprase Results to Be Presented at the AIM Symposium Thursday November 13, 4:30 pm ET --Nuvelo to Webcast the Phase 1 Data at a Meeting for the Financial Community On November 19, 2003-- SUNNYVALE, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Nuvelo, Inc. (Nasdaq: NUVO - News) today announced that the clinical data from its Phase 1 alfimeprase trial in patients with chronic peripheral arterial occlusion (PAO), will be presented at the Advanced Interventional Management (AIM) Symposium on November 18, 2003 in New York City. The presentation entitled, "Alfimeprase: A Novel New Thrombolytic Agent That May Reduce Complications And Improve Efficacy," will be given by Dr. Jacob Cynamon, professor of clinical radiology and director, division of vascular and interventional radiology at the Montefiore Medical Center and a principal investigator for Nuvelo's Phase 2 alfimeprase trial for the potential treatment of PAO.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next